IBSA Pharma – Recall of TIROSINT®-SOL (levothyroxine sodium) oral solution
February 1, 2023 - The FDA announced a consumer-level recall of 27 lots of IBSA Pharma’s TIROSINT-SOL (levothyroxine sodium) oral solution because these lots may be subpotent. The company’s analyses show a slight decrease below 95.0% of its labeled amount in levothyroxine sodium (T4) for some lots. This recall does not apply to TIROSINT® (levothyroxine sodium) capsules.
Top